A Combination-Product Supplier Change Is Not Closed Until the Evidence Connects
Combination-product supplier changes touch device, drug, and quality frameworks at once. Learn how to assess materials, process and test-method changes, notification routing, and closure criteria so the evidence chain stays intact.
By Melita Ball
A supplier change rarely stays inside one system
Combination products sit across device, drug, and sometimes biologic expectations. A supplier change to a component, material, process, or test method can therefore affect design controls, process validation, stability, container closure integrity, human factors, labeling, and regulatory filings at the same time.
The common failure is not that the change goes unnoticed. It is that the change is evaluated by one function against one framework and closed before the other implications are assessed. The record shows a completed change. The evidence chain does not show that the product remains as characterized.
Assess the change against every applicable framework
Build the impact assessment so that each relevant discipline records its own conclusion. Device engineering assesses design inputs, specifications, and verification. Manufacturing assesses process capability and validation status. Quality assesses controls and acceptance criteria. Clinical and human factors assess use-related risk. Regulatory assesses reporting and submission implications for each market.
Materials and interfaces
Material changes deserve particular scrutiny in combination products because interactions can be indirect. A resin, adhesive, coating, lubricant, or sterilization-compatible component change may affect extractables and leachables, drug stability, delivery performance, or biocompatibility conclusions. The assessment should identify which prior studies remain representative and which must be repeated.
Process and test-method changes
A supplier process change can shift variability even when the specification is unchanged. Consider whether validation remains applicable, whether sampling plans still detect the relevant failure modes, and whether historical data can be pooled with post-change data. For test-method changes, address equivalence before accepting results as comparable.
Notification and contractual reality
Quality agreements should define what the supplier must notify, when, and with what supporting information. Just as important is the internal routing: who receives the notice, who determines applicability, and what happens when a notice arrives after implementation. Retroactive assessment is sometimes unavoidable, but it should be recognized and documented as such.
Close the change only when the evidence connects
Define closure criteria that require the evidence chain to be intact: completed assessments from each function, executed protocols with results, resolved deviations, updated risk and design records, confirmed labeling status, regulatory determination with rationale, and effectiveness monitoring where appropriate.
First-article and ongoing-monitoring expectations should be explicit. A change that passes initial acceptance may still shift over subsequent lots. Define what will be monitored, for how long, and what result would reopen the assessment.
Prove it with one traceability walk
Take a recent supplier change and trace it forward: notification, applicability decision, impact assessments, protocols, results, approvals, implementation lot, labeling and filing status, and monitoring. Then trace it backward from a released lot to the approved change. If either direction requires narration, the chain is incomplete.
Combination-product teams tightening this discipline can connect it to supplier monitoring practice and a connected compliance system so that a supplier change and its consequences remain one continuous record.